UFPT · UFP Technologies

The thesis

UFP Technologies, a contract maker of medical-device components, is growing faster than its own long-term target, but its margins have not caught up yet. Its Dominican Republic program transfers are still behind plan. Third-quarter (Q3) 2026 organic growth was 11.1%, against a 6%–9% target. The fourth-quarter (Q4) report, expected around March 2027, will show whether growth stays above 6% against a harder comparison and whether gross margin rises above Q3's 29.4%.

The rating is Medium: the shares are judged modestly more likely than not to beat the S&P 500 over three months. Growth and profit both beat estimates in the 3 November 2026 release. The margin catch-up is the part of the case still unproven. Sales rose 11.6% to $172.4 million, and acquired operations contributed only $0.7 million of that. Nine-month organic growth was 7.9%. The 10-Q filed on 6 November 2026 confirmed quarterly revenue of $172.43 million, against $154.56 million a year earlier.

The price has given back much of the post-report jump. The shares closed at $305.91 on 12 November 2026, 10.6% below the $342.11 intraday high reached on 4 November 2026, the day after the report. Stock Analysis puts the $357.50 consensus target 16.86% above that close. The pullback suggests the market is pricing the margin delay rather than the growth beat. A Q4 gross margin above 29.4% would test that discount.

Bullish and bearish views on UFP Technologies, Inc.

The bull case on UFP Technologies, Inc. (UFPT), in brief: organic growth is above target. The bear case: Dominican Republic gains are late.

Bull case

• Organic growth is above target. Q3 organic growth was 11.1%, according to the 3 November 2026 release, and MedTech sales grew 12.5%. Management reiterated the 6%–9% long-term target on the 4 November 2026 call.
• Results beat estimates. Benzinga reported on 3 November 2026 that adjusted EPS (earnings per share) of $2.88 beat the $2.69 estimate. Sales of $172.434 million beat the $166.887 million estimate.
• Profit grew faster than sales. Q3 net income rose 25.8% to $20.6 million on 11.6% sales growth, per the 3 November 2026 release. Adjusted operating income rose 14.5% to $30.1 million.
• Gross margin is up year over year. Q3 gross margin was 29.4%, against 27.7% a year earlier. StockStory reported on 4 November 2026 that management expects gross margin to stay in a 28%–31% range and the AJR transfer to bring further margin gains in 2027.
• Debt is modest and deals are in view. At 30 September 2026 the company reported $20.6 million of cash, $12.5 million of current debt and $83.5 million of long-term debt. Q3 adjusted EBITDA (earnings before interest, taxes, depreciation and amortization) was $35.4 million. StockStory reported on 4 November 2026 that management called the acquisition pipeline active, with an expanded credit facility behind it. In August the company bought CI Medical, a printing business for medical devices.

Bear case

• Dominican Republic gains are late. The 3 November 2026 release says "scheduled program transfers to the Dominican Republic and margin improvement remain behind plan." Gross margin rose only from 29.3% in Q2 to 29.4% in Q3. StockStory reported on 4 November 2026 that the AJR move is now expected to finish by 2027, with no quarter given.
• Q3 lapped an easy comparison. On the Q3 2025 call, the chief financial officer said organic sales that quarter "were essentially flat." Q4 and the 2027 quarters face stronger comparisons.
• Robotic surgery is soft. Call coverage of the 4 November 2026 call reports that management expects robotic surgery growth in 2026 to be flat to down. Robotic surgery is tied to the company's largest customer.
• Analysts are split. Stock Analysis showed four analysts as of 10 November 2026: one Strong Buy, one Buy and two Hold. Its monthly rating counts have not changed from March through November 2026, and the 2026 EPS estimate stands at $10.80.
• Directors sold above today's price. SEC Form 4 filings show director Cynthia L. Feldmann selling 1,000 shares at $324.26 on 13 August 2026. Director Symeria Hudson sold 1,926 shares at $324.58 on 14 August 2026. Director Marc D. Kozin sold 7,000 shares at an average of $304.50 on 25 August 2026.

Price setup

The shares closed at $305.91 on 12 November 2026, down from $318.86 on 9 November 2026. The 52-week intraday high of $342.11 came on 4 November 2026, the session after the report. The 52-week closing low was $185.45 on 29 April 2026. The 3-month change is −4.9%, measured from a $321.76 close on 14 August 2026.

The 12 November 2026 close sits above both the 50-day moving average of $292.58 and the 200-day moving average of $251.41. The 50-day average marks the first nearby level. The September recovery started from intraday lows on 15 September 2026 and 18 September 2026. A close back under those lows would undo the recovery. All four analyst targets, from $350 to $365 on Stock Analysis, sit above the 12 November 2026 close.

The next scheduled company update is the Q4 report, about four months away. Until then the shares have no company event of their own to trade on.

Catalysts ahead

• ~1 March 2027 (est.): Q4 2026 results; the company had not announced a date as of 12 November 2026. Shows whether organic growth stays above 6% against a harder comparison and whether gross margin rises from 29.4% as the Dominican Republic transfers progress.

What would change the view

A weekly close below $273, under the 15 September 2026 and 18 September 2026 intraday lows that began the September recovery, which would erase that recovery. Q4 2026 organic growth below 6%, the low end of the company's long-term target, or gross margin below 28% would also break the case.

The risks this note tracks, each with what would confirm it:

• Q3's double-digit growth reflected an easy year-ago comparison, when Q3 2025 organic sales were essentially flat, and fades as comparisons get harder. Confirmed by: Q4 2026 organic growth below 6%, the low end of the company's long-term target.
• Dominican Republic transfers slip further and hold down margins. Confirmed by: Q4 gross margin below Q3's 29.4%, with management again describing transfers as behind plan or moving the AJR completion past 2027.
• Robotic surgery weakness at the largest customer extends past 2026. Confirmed by: management describing 2027 robotic surgery growth as flat or down at the Q4 report.
• Analyst support erodes after the Q3 report. Confirmed by: a cut to the $357.50 consensus target or a downgrade among the four covering analysts.
• Continued director selling signals limited insider conviction at current prices. Confirmed by: new SEC Form 4 filings showing further director or officer open-market sales after the 3 November 2026 report.
• An acquisition strains integration or the balance sheet. Confirmed by: a deal announcement that lifts debt well above the $96.0 million of current and long-term debt reported at 30 September 2026, or integration costs flagged at the Q4 report.

What it trades with

The shares move on company-specific results more than on a broad theme. Demand runs through medical-device makers. MedTech is the largest end market, and the largest customer is tied to robotic surgery. Weak procedure volumes or inventory cuts at large device makers would hit the company. US tariff policy on medical components imported from the Dominican Republic feeds directly into gross margin.

With four covering analysts, one revision can move the consensus target. UFP Technologies is often confused with UFP Industries (Nasdaq: UFPI), a lumber and building-products company whose results have no bearing on it.